Market Place
Sourcing Support
All News #Library
Biotech
LIB Therapeutics Presents LEROCHOL Data ACC 2026
30 Mar 2026 //
BUSINESSWIRE
FDA Approves LIB Therapeutics` LEROCHOL For High LDL Cholesterol
15 Dec 2025 //
BUSINESSWIRE
LIB Therapeutics Unveils Late-Breaking Data At 2025 AHA
10 Nov 2025 //
BUSINESS WIRE
Lerodalcibep May Help Patients Needing More LDL-C Reduction
04 Mar 2025 //
EXPRESSPHARMA
LIB Therapeutics Announces FDA Acceptance of BLA for Lerodalcibep
10 Feb 2025 //
BUSINESSWIRE
LIB’s Lerodalcibep HoFH Phase 3 Study Published in Lancet Diabetes
27 Jan 2025 //
BUSINESSWIRE
LIB Therapeutic Submits BLA for Lerodalcibep to Treat Elevated LDL
16 Dec 2024 //
BUSINESSWIRE
LIB`s Lerodalcibep Positive Phase 3 Data At EAS Congress
29 May 2024 //
BUSINESSWIRE
Lib Lerodalcibep Eas Abstracts: 92nd Congress Presentations Accepted
23 May 2024 //
BUSINESSWIRE
LIB & Partner Hasten Announce Lerodalcibep Clinical Trial
19 Mar 2024 //
BUSINESSWIRE
LIB Therapeutics Announces Appointment of Ingrid Choong as CBO
07 Dec 2023 //
BUSINESSWIRE
LIB Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep
14 Nov 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.